Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis
Abstract Background Anti-angiogenesis treatments are the most commonly used treatments for the vision loss caused by exudative age-related macular degeneration (AMD), in which the anti-vascular endothelial growth factor (VEGF) drugs with ranibizumab and bevacizumab are current standard treatments. H...
Main Authors: | Ya-li Zhou, Chun-li Chen, Yi-xiao Wang, Yao Tong, Xiao-ling Fang, Lin Li, Zhao-yang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-017-0487-2 |
Similar Items
-
New Therapies of Neovascular AMD—Beyond Anti-VEGFs
by: Praveen Yerramothu
Published: (2018-07-01) -
Association of Htra1 Gene Polymorphisms with the Risk of Developing AMD in Iranian Population
by: Mohammad Askari, et al.
Published: (2015-10-01) -
Progress in the Study of the Role and Mechanism of HTRA1 in Diseases Related to Vascular Abnormalities
by: Song S, et al.
Published: (2024-04-01) -
HTRA1 rs11528744, BCRA1 rs9928736, and B3GLCT rs4381465 are associated with age-related macular degeneration in a Chinese population
by: Guo Huang, et al.
Published: (2022-09-01) -
HTRA1 rs11200638 variant and AMD risk from a comprehensive analysis about 15,316 subjects
by: Ying Liu, et al.
Published: (2020-05-01)